镭-223在前列腺癌临床实践中的整合应用:当前策略
本文综述了镭-223(radium-223)在转移性去势抵抗性前列腺癌(mCRPC)中的临床应用。镭-223是一种靶向α治疗,可延长总生存并延迟首次症状性骨骼事件,适用于有症状骨转移且无已知内脏转移的CRPC患者。文章基于临床经验与试验数据,提供患者选择、患者教育及序贯/联合治疗的实践指导,并建议在mCRPC骨转移患者治疗过程中相对早期考虑使用镭-223。
要点
- 镭-223适用于有症状骨转移且无已知内脏转移的CRPC患者。
- 镭-223可延长mCRPC男性总生存并延迟首次症状性骨骼事件。
- 基于临床经验,mCRPC骨转移患者应相对早期考虑镭-223。
核心结论
- 基于临床经验,mCRPC骨转移患者应在治疗过程中相对早期考虑镭-223。
- 多学科团队、患者与照护者的协作对优化所有CRPC治疗的安全有效至关重要。
研究设计与样本
- 本文为综述,基于作者集体临床经验及现有临床试验数据,提供镭-223整合入mCRPC管理的实践指导。
主要发现
- 镭-223是一种靶向α治疗,作为骨靶向钙模拟物,聚集于肿瘤病灶周围的羟基磷灰石区域,选择性结合骨转换增加区域。
- 镭-223延长mCRPC男性总生存并延迟首次症状性骨骼事件。
- 镭-223适用于CRPC、有症状骨转移且无已知内脏转移患者的治疗。
- 综述还总结了近期关于镭-223序贯和联合治疗的证据及作者经验。
关键数值与推荐
- 镭-223适用于CRPC、有症状骨转移且无已知内脏转移的患者。
- 基于临床经验,mCRPC骨转移患者应相对早期考虑镭-223。
临床怎么用
- 基于临床经验,mCRPC骨转移患者应在治疗过程中相对早期考虑镭-223。
- 需向拟接受治疗的患者提供教育和信息以支持治疗决策。
- 多学科团队、患者与照护者的协作对优化CRPC治疗的安全有效至关重要。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Treatment options for metastatic castration-resistant prostate cancer (mCRPC) have expanded in recent years and include cytotoxic agents (e.g., docetaxel and cabazitaxel), immunotherapy (e.g., sipuleucel-T), oral hormonal therapies targeting the androgen receptor axis (e.g., enzalutamide and abiraterone), and targeted alpha therapy (e.g., radium-223 dichloride (radium-223)). Although treatment guidelines have been updated to reflect the availability of new agents, it is not easy to apply them in daily clinical practice because recommendations vary depending on patient comorbidities and disease characteristics. Furthermore, therapeutic accessibility, clinical judgment, and experience affect the selection of treatment options. METHODS: In this review, we provide practical guidance for the integration of radium-223 into the management of patients with mCRPC based on our collective clinical experience, as well as the available clinical trial data. RESULTS: Radium-223 is a targeted alpha therapy; as a bone-seeking calcium mimetic, it accumulates in hydroxyapatite areas surrounding tumor lesions and selectively binds to the areas of increased bone turnover. Radium-223 prolongs overall survival and delays time to the first symptomatic skeletal events in men with mCRPC, and is indicated for the treatment of patients with CRPC, symptomatic bone metastases, and no known visceral metastases. We review its clinical efficacy and safety, practical guidance on identifying the appropriate patient, and recommendations for how best to educate and inform prospective patients regarding their treatment decision making. In addition, we review recent evidence for sequential and combination therapies with radium-223, provide our experiences with these treatment approaches, and discuss their implications for the future treatment of patients with mCRPC. CONCLUSIONS: Based on our clinical experience, radium-223 should be considered relatively early in the treatment course in patients with mCRPC with bone metastases. Coordination of care among multidisciplinary team members, patients, and caregivers is essential for optimizing safe and effective treatment with all CRPC therapies.
引用
- Parker C, Heidenreich A, Nilsson S, et al. Current approaches to incorporation of radium-223 in clinical practice. Prostate Cancer Prostatic Dis. 2018. PMID: 29298991. doi:10.1038/s41391-017-0020-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。